Title : Mechanisms of mesenchymal stem cells and MSC- Exo in therapy of infection-related ARDS
Abstract:
Mesenchymal stem cells (MSCs) and their exosomes (MSC-Exo) are promising for treating infection-induced Acute Respiratory Distress Syndrome (ARDS), mainly via paracrine effects involving immunomodulation, anti-inflammation, antimicrobial activity, and tissue repair, rather than direct cell replacement.
Infections (e.g., bacterial pneumonia, sepsis) cause ARDS, whose pathology involves uncontrolled inflammatory cytokine storms and disrupted pulmonary endothelial-epithelial barriers, leading to edema and respiratory failure. Their core mechanisms are as follows:
I. Immunomodulation and Anti-Inflammation: This is the key mechanism. MSCs and MSC-Exo promote M1-to-M2 macrophage polarization via miRNAs (e.g., miR-223, miR-146a), inhibit neutrophil infiltration/NETosis, suppress pro-inflammatory Th1/Th17 cells while enhancing regulatory T cells, and reduce pro-inflammatory cytokines (e.g., TNF-α, IL-6) via soluble factors (e.g., PGE2, TGF-β), elevating anti-inflammatory IL-10.
II. Antimicrobial Activity: They enhance pathogen clearance by boosting M2 macrophage phagocytosis, secreting antimicrobial peptides (e.g., LL-37), transferring mitochondria to restore cellular energy and bactericidal capacity, and upregulating endogenous antimicrobial peptides via MSC-Exo miRNAs.
III. Tissue Repair: They promote alveolar fluid clearance via VEGF/KGF, protect endothelial/epithelial cells from apoptosis, upregulate tight junction proteins (e.g., occludin), stimulate alveolar type II cell proliferation, and inhibit pulmonary fibrosis via TGF-β1/Smad pathway modulation.
IV. MSC-Exo Advantages: As cell-free mediators, they avoid live cell risks (e.g., embolism, rejection), target injured sites specifically, protect cargo (miRNAs, proteins) via lipid bilayers, with miRNAs as core components regulating inflammation and barrier function.
Preclinical studies and early clinical trials (I/II) confirm safety and efficacy. Key challenges include optimizing cell sources/dosing, standardizing exosome production, and addressing efficacy heterogeneity across ARDS etiologies.
In summary, MSCs and MSC-Exo treat infection-induced ARDS via synergistic effects: suppressing inflammation, combating infection, and repairing tissue.
